Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.44 |
| ▸ | ECE1 | P42892 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154874 | 0.92 | F10 (0.46) | ECE1CCR2ABCB1 | |
| SCHEMBL3150083 | 0.83 | NPC1 (0.48) | PPARGECE1CCR2 | |
| SCHEMBL3149734 | 0.82 | ALDH1A1 (0.48) | PPARGECE1CCR2 | |
| SCHEMBL3154197 | 0.82 | MAPT (0.48) | PPARGECE1CCR2 | |
| SCHEMBL3154163 | 0.81 | PPARG (0.47) | PPARGECE1CCR2 | |
| SCHEMBL3157995 | 0.81 | KIF11 (0.47) | PPARGECE1CCR2ABCB1 | |
| SCHEMBL3157525 | 0.81 | NPC1 (0.48) | PPARGECE1CCR2 | |
| SCHEMBL3149353 | 0.80 | ECE1 (0.48) | PPARGECE1CCR2 | |
| SCHEMBL3154395 | 0.80 | PPARG (0.46) | PPARGECE1CCR2 | |
| SCHEMBL3156981 | 0.80 | MAPT (0.51) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841737-B1 | N-(HETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2010-03-10 | — | — | EP | claimed |
| EP-1841737-B1 | N-(HETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2010-03-10 | — | — | EP | disclosed |
| US-7557134-B2 | N-(heteroaryl)-1H-indole-2-carboxamide derivatives and their use as vanilloid TRPV1 receptor ligands | SANOFI-AVENTIS (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080255131-A1 | N-(HETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2008-10-16 | — | — | US | disclosed |
| US-7407950-B2 | N-(heteroaryl)-1H-indole-2-carboxamide derivatives and their use as vanilloid TRPV1 receptor ligands | SANOFI-AVENTIS (FR) | 2008-08-05 | — | — | US | disclosed |
| US-20070259946-A1 | N-(isoquinol-5-yl)-5-fluoro-1-[((3-trifluoromethyl)phenyl)methyl]-1H-indole-2-carboxamide; transient receptor potential vanilloid (capsaicin receptor) antagonist or agonist; analgesic, antiallergen agent; pain and irritation of the skin, eyes and mucous membrane | SANOFI-AVENTIS (FR) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259946-A1 | N-(isoquinol-5-yl)-5-fluoro-1-[((3-trifluoromethyl)phenyl)methyl]-1H-indole-2-carboxamide; transient receptor potential vanilloid (capsaicin receptor) antagonist or agonist; analgesic, antiallergen agent; pain and irritation of the skin, eyes and mucous membrane | TRPV1, TRPV5, TRPA1 | PPARG 1293/4885ECE1 2717/4885CCR2 223/4885 |
| US-20080255131-A1 | N-(HETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | TRPV1, TRPV3, TRPV2 | PPARG 569/4885ECE1 2605/4885CCR2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.